

## Editorial Board

### Kathryn Bayne, MS, PhD, DVM

Senior Director and Director of Pacific Rim Activities, AAALAC International, Hilo, HI.

### Joseph T. Bielitzki, MS, DVM

Program Manager, Defense Sciences Office, Defense Advanced Research Projects Agency, Arlington, VA.

### J. Roger Broderson, DVM, PhD

Mercer University Veterinarian, Atlanta-Macon, GA.

### Cyndi Brown, DVM

Associate Staff, Department of Avian and Exotic Pets, The Animal Medical Center, New York, NY.

### Thomas M. Donnelly, DVM

The Kenneth S. Warren Institute, Ossining, NY.

### Nina Hahn, DVM, PhD, DACLAM

Associate Director, Office of Laboratory Animal Care, University of California Berkeley, Berkeley, CA.

### Victoria Hampshire, VMD

Advanced Veterinary Applications, Bethesda, MD.

### John M. Hicks, DVM, MPH

Veterinary Consultant, Pikesville, MD.

### Paul Houghton

Biologist, Primate Products, Redwood City, CA.

### Robert F. Hoyt, Jr., DVM, MS

Chief, Laboratory Animal Medicine and Surgery, National Heart Lung and Blood Institute, NIH, Bethesda, MD.

### Mary Lou James, BA, RLATG

Consultant, Regulatory Compliance, St. Louis, MO.

### Bruce W. Kennedy, MS, RLATG

Facility Manager, Transgenic Core Facility, California Institute of Technology, Pasadena, CA.

### Joseph Knapka, PhD

Consultant, Laboratory Animal Nutrition, Brookeville, MD.

### C. Max Lang, DVM

Professor and Chairman, Department of Comparative Medicine, Milton S. Eshelby Medical Center, Pennsylvania State University, Hershey, PA.

### Richard H. Latt, DVM

Director, Animal Resources Centre, McGill University, Montreal, Quebec, Canada.

### Sherry M. Lewis, PhD

Nutritionist/Research Scientist, National Center for Toxicological Research, Jefferson, AR.

### Carol Cutler Linder, PhD

Assistant Professor of Biology, New Mexico Highlands University, Las Vegas, NM.

### John A. Maher, MS, MBA, CMAR, RLATG

Senior Manager, BioResources, Wyeth Research, Pearl River, NY.

### Fred W. Quimby, VMD, PhD

Director, Lab Animal Research Center, Rockefeller University, New York, NY.

### John Curtis Seely, DVM, ACVP

Veterinary Pathologist, Experimental Pathology Laboratories, Research Triangle Park, NC.

### Moshe Shalev, MSc, VMD

Plum Island Animal Disease Center, Greenport, NY.

### Jo Ellen Sherow, BS, LATG

Director, Research Compliance, Ohio University, Athens, OH.

### Jerald Silverman, DVM

Professor and Director, Department of Animal Medicine, University of Massachusetts Medical School, Worcester, MA.

### Michael K. Stoskopf, DVM, PhD

Professor and Director of Environmental Medicine Consortium, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.

### Paul J. Upman, PhD

Senior Scientist, NAMSA, Northwood, OH.

### Robert H. Weichbrod, PhD, MBA, RLATG

Animal Program Administrator, National Eye Institute, NIH, Bethesda, MD.

### Steven H. Weisbroth, DVM

Consultant, Taconic Anmed, Rockville, MD.

### Axel Wolff, MS, DVM

Senior Assurance Officer, Division of Assurances, OLA, NIH, Bethesda, MD.

## Taking the Guesswork out of Toxicology

Cancer is now the #1 killer of Americans under 85, having just surpassed heart disease for the top spot. The death rates from both conditions are actually declining, due to prevention efforts and more effective treatments, but the drop off has been faster for heart disease. Although some cancers are hereditary by nature, most experts agree that environmental factors, including food choices and workplace exposures, are important contributors to the onset and development of cancer.

While it may not be possible to avoid exposure to all carcinogens, knowing which compounds pose a risk may help individuals to limit contact with these chemicals. To fill this need, every two years, the National Toxicology Program (NTP), an interagency program within the US Department of Health and Human Services (HHS), issues a report that lists all known and probable human carcinogens to which a substantial part of the population may be exposed.

On 31 January, HHS released the Eleventh Edition of the *Report on Carcinogens*. With the addition of 17 substances, the report now lists 58 known and 188 suspected carcinogens, and offers detailed information on these compounds, including the nature of exposure risk and the number of persons exposed to such substances. In compiling the list, the NTP considers both human and laboratory animal studies conducted by government research agencies, academia, industry, and other research organizations that have been published in the scientific literature to determine whether substances are potential human carcinogens.

Although human epidemiological studies provide the strongest evidence of a substance's cancer-causing potential, this type of data is not always available. Therefore, one of the three criteria for deeming a compound "reasonably anticipated to be a human carcinogen" is that "there is sufficient evidence of carcinogenicity from studies in experimental animals, which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors (1) in multiple species or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site, or type of tumor, or age at onset!"

Carcinogenicity is just one of the effects that researchers are looking for when they do safety assessment testing of compounds, such as new drugs. Since these tests are vitally important, it is imperative that *in vivo* toxicology studies are properly conducted, well documented, and reproducible. To ensure that tests are properly conducted, the US Food and Drug Administration (FDA) enforces their Good Laboratory Practice Regulations (GLPs) for safety assessment studies of all drugs, food additives, and cosmetics. Likewise, the US Environmental Protection Agency (EPA), has devised similar regulations for the testing of pesticides and industrial chemicals.

Despite the importance of *in vivo* safety assessment studies, many individuals working in laboratory animal science may be unfamiliar with these standards. In this issue, we present two articles that introduce the readers to the GLPs. On p. 29, Joe Cwierniewicz presents a primer on these regulations, and on p. 35, Denise Fillman-Holiday draws on her experience working in various roles within the safety assessment arena to discuss the role of the laboratory animal veterinarian in the conduct of these studies.

## Reference

1. US Department of Health and Human Services, Public Health Service, National Toxicology Program. *Report on Carcinogens* 11<sup>th</sup> edn. <http://ntp-server.niehs.nih.gov/ntp/roc/toc11.html>.